In a dramatic turn of events, aTyr Pharma, Inc. finds itself at the center of a class action lawsuit following the disappointing results of its Efzofitimod trial. Shareholders are seeking to recoup losses incurred between January 16, 2025, and September 12, 2025, due to alleged securities fraud. The lawsuit claims that aTyr misled investors with overly optimistic statements about the drug’s potential, particularly its ability to allow patients to completely taper off steroids.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The truth came to light on September 15, 2025, when aTyr revealed in an investor call that the EFZO-FIT study failed to meet its primary endpoint. The announcement, which highlighted the study’s inability to show a significant change from baseline in mean daily OSC dose at week 48, sent shockwaves through the market. Consequently, aTyr’s stock plummeted from $6.03 to $1.02 per share, marking an 83.2% drop in just one day.
For those who suffered losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit https://zlk.com/pslra-1/atyr-pharma-inc-lawsuit-submission-form?wire=18 to learn more about their rights. Participation comes with no cost or obligation.
The lawsuit is being spearheaded by Levi & Korsinsky LLP, a firm renowned for its prowess in securities litigation. With over 20 years of experience and a track record of recovering hundreds of millions for shareholders, the firm stands as a formidable advocate for investors. Levi & Korsinsky’s reputation is further solidified by its consistent ranking in the ISS Securities Class Action Services’ Top 50 Report.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171